Literature DB >> 3033095

Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model.

J M Matthews-Greer, H E Gilleland.   

Abstract

Outer membrane (OM) protein F (porin) was purified by extraction from polyacrylamide gels of cell envelope proteins of the Pseudomonas aeruginosa PA01 strain. Mice were immunized intramuscularly with 10 micrograms of protein F preparation on days 1 and 14 and then subjected to burn and challenge on day 28. Protein F immunization afforded significant protection above that provided by PA01 lipopolysaccharide (LPS) immunization against subsequent challenge with six of six heterologous LPS immunotype strains of P. aeruginosa. By an ELISA, the murine immune response revealed an IgG titer of 5,120 to protein F by day 30. Immunoblot analysis of antisera from protein F-immunized mice revealed bands with both protein F and protein H of cell envelopes of all immunotypes tested. Active immunization with OM protein H did not, however, afford significant protection to mice in this burned mouse model. These data show the efficacy of OM protein F as a protective vaccine in a murine model representative of human infection.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3033095     DOI: 10.1093/infdis/155.6.1282

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  35 in total

1.  Pseudomonas aeruginosa immunotherapy.

Authors:  J E Pennington
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-06       Impact factor: 3.267

2.  Sequence and transcriptional start site of the Pseudomonas aeruginosa outer membrane porin protein F gene.

Authors:  M Duchêne; A Schweizer; F Lottspeich; G Krauss; M Marget; K Vogel; B U von Specht; H Domdey
Journal:  J Bacteriol       Date:  1988-01       Impact factor: 3.490

Review 3.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

4.  Chronic Infection by Mucoid Pseudomonas aeruginosa Associated with Dysregulation in T-Cell Immunity to Outer Membrane Porin F.

Authors:  Kathryn J Quigley; Catherine J Reynolds; Amelie Goudet; Eleanor J Raynsford; Ruhena Sergeant; Andrew Quigley; Stefan Worgall; Diana Bilton; Robert Wilson; Michael R Loebinger; Bernard Maillere; Daniel M Altmann; Rosemary J Boyton
Journal:  Am J Respir Crit Care Med       Date:  2015-06-01       Impact factor: 21.405

5.  Protection against experimental Pseudomonas aeruginosa infection by recombinant P. aeruginosa lipoprotein I expressed in Escherichia coli.

Authors:  M Finke; M Duchêne; A Eckhardt; H Domdey; B U von Specht
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.441

Review 6.  Perspectives on the potential for successful development of outer membrane protein vaccines.

Authors:  H E Gilleland; J M Matthews-Greer
Journal:  Eur J Clin Microbiol       Date:  1987-06       Impact factor: 3.267

7.  Protective immunization against experimental Bacteroides (Porphyromonas) gingivalis infection.

Authors:  P B Chen; L B Davern; R Schifferle; J J Zambon
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

8.  Protection against Pseudomonas aeruginosa chronic lung infection in mice by genetic immunization against outer membrane protein F (OprF) of P. aeruginosa.

Authors:  B M Price; D R Galloway; N R Baker; L B Gilleland; J Staczek; H E Gilleland
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

9.  Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid.

Authors:  Stefan Worgall; Anja Krause; Michael Rivara; Kyung-Kim Hee; Enrico V Vintayen; Neil R Hackett; Peter W Roelvink; Joseph T Bruder; Thomas J Wickham; Imre Kovesdi; Ronald G Crystal
Journal:  J Clin Invest       Date:  2005-04-01       Impact factor: 14.808

10.  Synthetic peptides representing epitopes of outer membrane protein F of Pseudomonas aeruginosa that elicit antibodies reactive with whole cells of heterologous immunotype strains of P. aeruginosa.

Authors:  E E Hughes; L B Gilleland; H E Gilleland
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.